Shares of Thyrocare Technologies gained significant attention today, reaching a 52-week high following the release of strong Q2 results. The company reported a standalone net profit of ₹43.04 crore for the quarter ending September 2025, marking a 45 percent increase from ₹29.59 crore in the same period the previous year.
Revenue from operations rose by 24 percent to ₹202.23 crore compared to ₹163.05 crore in the corresponding quarter last year. The company’s board also declared an interim dividend of ₹7 per share, with October 24, 2025, set as the record date for this distribution. Additionally, the board approved a bonus share issuance in a 2:1 ratio.
Consolidated EBITDA for the company grew by 48 percent year-over-year, while profit after tax (PAT) saw a remarkable 82 percent annual increase, as stated in the company’s official announcement.
Alok Kumar Jagnani, Group CFO of Thyrocare Technologies, commented, “The Q2 performance reflects the strength of our business fundamentals, disciplined financial management, and the unwavering commitment of our teams. As we mark 25 years of trust and innovation, the bonus share announcement underscores our commitment to our shareholders and investors and reinforces our confidence in long-term growth.”
Despite the positive results, Thyrocare’s stock retraced its early gains and ultimately closed nearly 2 percent lower at ₹1,241.90 on the Bombay Stock Exchange (BSE).
Published on October 15, 2025.
